1 / 10

ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailur

ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailure. Duke Heart Failure Research Pager: 970-0736. Purpose.

liam
Download Presentation

ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailur

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASCEND-HFAcute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure Duke Heart Failure Research Pager: 970-0736

  2. Purpose • Double blinded placebo-controlled study to evaluate efficacy and safety of Nesiritide (Natrecor) in addition to standard care vs. placebo with standard care in patients with acute decompensated heart failure. • Double blinded study meaning subjects, MD, and research team are unaware of what treatment is being received.

  3. Nesiritide(Natrecor) – A medication used to treat acute decompensted HF. It is a form of human BNP that promotes vasodilation, natriuresis, and diuresis.

  4. Dyspnea at rest Pulmonary congestion Signs/symptoms within 24 hrs of admission Inclusion Criteria

  5. Interventions • USE OF OPEN LABEL NESIRITIDE IS NOT ALLOWED AT ANY TIME!!

  6. See “Protocol Instructions” and follow titration directions.This information is kept in patient’s chart box. • Side effects of Nesiritide (see Adverse Reactions List): http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=2134&sec=monadve

  7. Nursing Roles • Nesiritide infusion of 0.010 mcg/kg/min with or without 2mcg/kg bolus vs. placebo • Change bag every 24 hrs. • Monitor VS q 5min. x4, q 30min. x2, and then q hr. x4

  8. Nursing Roles • Ask subjects to fill out questionnaires* and Visual Analog Scales (VAS)* at 6 and 24 hrs • QUESTIONNAIRES and VAS INCLUDE: • Dyspnea self assessments • Health status/well-being, mobility, self-care, pain, depression, activities *Found in patient’s chart box.

  9. Outcomes • Why is this study being done? • Does Nesiritide decrease re-hospitalization or death in 30 days? • Does Nesiritide decrease symptoms of dyspnea at 6 and 24 hrs after drug initiated?

  10. Outcomes • Measure overall well-being at 6 and 24 hrs • Measure # of days alive and # of days outside hospital from randomization to day 30 • Measure cardiovascular re-hospitalization and mortality from randomization to day 30

More Related